What Does Flibanserin Actually Cost per Unit of Benefit? BEGONIA Trial Economics Explained

At a glance

• Trial: BEGONIA (NCT00996372)
• N: 949 premenopausal women with generalized acquired HSDD
• Intervention: Flibanserin 100 mg nightly
• Comparator: Placebo
• Duration: 24 weeks
• Primary endpoint: Change in number of satisfying sexual events (SSEs)
• Key result: Statistically significant increase of ~0.8 SSEs/month over placebo (Katz et al., 2013)

The Efficacy Denominator: What BEGONIA Actually Delivered

Before any cost calculation makes sense, you need the effect size. In BEGONIA, women randomized to flibanserin 100 mg nightly reported approximately 0.8 additional satisfying sexual events per month compared to placebo (Katz et al., 2013). The co-primary endpoints (Female Sexual Function Index desire domain and Female Sexual Distress Scale-Revised Item 13) also showed statistically significant but clinically modest separation from placebo. The number needed to treat for a "much improved" or "very much improved" rating on the Patient Global Impression of Improvement hovered near 8 to 10 across the key trials.

This effect size is the denominator for every economic model. Small denominators make cost-effectiveness ratios large. That arithmetic reality has defined flibanserin's health-economic story from the start.

List Price, Net Price, and the Gap Between Them

When Sprout Pharmaceuticals launched Addyi in October 2015, the wholesale acquisition cost (WAC) was set at approximately $800 per month. After Valeant (now Bausch Health) acquired Sprout, the WAC was maintained but a savings program reduced patient cost to as low as $75/month for commercially insured patients meeting program criteria (Addyi prescribing information, FDA).

The current list price remains approximately $400 to $450 for a 30-day supply through retail pharmacies, though significant variation exists by distributor. Net prices after manufacturer rebates and copay assistance are substantially lower for enrolled patients. Uninsured patients or those whose plans exclude flibanserin face the full WAC or generic equivalents, which became available after 2019 and now cost approximately $30 to $100/month depending on the pharmacy (FDA Orange Book).

Generic entry changed the economics dramatically. A patient paying $50/month for generic flibanserin faces a fundamentally different value proposition than one paying $400 for branded Addyi.

Published Cost-Effectiveness Models

Formal cost-effectiveness analyses of flibanserin are limited. No manufacturer-sponsored cost-utility analysis was published in a peer-reviewed journal prior to FDA approval. The economic evidence that does exist comes from independent academic groups and health technology assessment bodies.

The QALY Problem

HSDD lacks a validated mapping from clinical trial endpoints (SSE counts, FSFI scores) to quality-adjusted life years. This is not unique to flibanserin; it affects the entire category of sexual dysfunction therapies. Without a direct FSFI-to-EQ-5D mapping, analysts must make assumptions about how much an additional 0.8 SSEs per month contributes to overall health-related quality of life (Joffe et al., 2016).

Estimates from the limited modeling literature place the QALY gain from flibanserin treatment at 0.01 to 0.04 per year. At the branded list price of ~$4,800/year, that produces an incremental cost-effectiveness ratio (ICER) of $120,000 to $480,000 per QALY, well above the commonly cited $50,000 to $150,000/QALY willingness-to-pay threshold used in U.S. payer decisions (Neumann et al., 2014).

At generic pricing of ~$600 to $1,200/year, the ICER drops to $15,000 to $120,000 per QALY, a range that straddles conventional thresholds. For patients at the higher end of QALY gain (those with severe baseline distress who respond well), generic flibanserin can reach cost-effectiveness benchmarks.

Comparison to PDE5 Inhibitors for Male Sexual Dysfunction

The gender-equity argument featured prominently in the FDA approval debate. Generic sildenafil costs approximately $10 to $30/month and produces a substantially larger effect size for erectile dysfunction (roughly 60% to 70% of men achieve erections sufficient for intercourse versus ~25% on placebo) (Goldstein et al., 1998). The cost-per-responder for generic sildenafil is an order of magnitude lower than for branded flibanserin, though this comparison conflates different conditions, different endpoints, and different mechanisms of action.

The comparison is more balanced when generic flibanserin is measured against branded bremelanotide (Vyleesi), which costs approximately $900 per dose pack (8 autoinjectors). Bremelanotide's RECONNECT trials showed a similar effect magnitude to flibanserin's key studies, including BEGONIA (Kingsberg et al., 2019). On a per-month basis, bremelanotide is substantially more expensive for women using it at the maximum frequency.

Payer Coverage: The Practical Economics

Commercial Insurance

Most large commercial plans initially excluded flibanserin from formularies. As of 2025, coverage remains inconsistent. Plans that do cover it typically require prior authorization with documentation of (ISSWSH guidelines):

• Confirmed HSDD diagnosis (not desire discrepancy or medication-induced)
• Trial of non-pharmacologic interventions
• No contraindicated alcohol use
• Prescriber attestation regarding the REMS program

Step therapy requirements sometimes mandate psychotherapy or hormonal evaluation before approval. Copays for covered patients range from $0 (with manufacturer coupon stacking) to $75.

Medicare and Medicaid

Medicare Part D plans rarely cover flibanserin. Medicaid coverage varies by state, with many state Medicaid programs listing it as non-preferred or excluded entirely. The Medicaid Drug Rebate Program does apply, but prior authorization requirements are stringent in most states.

The REMS Factor

The FDA-mandated REMS (Risk Evaluation and Mitigation Strategy) for flibanserin requires certified prescriber and pharmacy enrollment due to the alcohol interaction risk (FDA REMS page). This adds administrative cost for providers and limits pharmacy access, creating a friction cost that does not appear in traditional economic models but materially affects patient access. The REMS was simplified in 2019, removing the patient-prescriber agreement form, but certified pharmacy dispensing requirements remain.

Individual Value Calculation: Is It Worth It for You?

Population-level ICERs tell payers whether to cover a drug. They tell individual patients very little. A woman considering flibanserin after BEGONIA's data needs a different framework.

The responder question. In BEGONIA, approximately 46% to 50% of flibanserin-treated women rated themselves as "improved" on the PGI-I versus ~35% on placebo (Katz et al., 2013). That means roughly 1 in 8 to 10 women experiences meaningful improvement attributable to the drug rather than placebo effects. For the responder, the value may be high. For the non-responder, the value is zero plus the cost of side effects (somnolence, dizziness, nausea).

Time to assess. BEGONIA and its companion trials suggest that response can be evaluated within 8 weeks. The FDA label recommends discontinuation if no improvement occurs by 8 weeks (Addyi label). At generic pricing, an 8-week trial costs $100 to $200, a reasonable diagnostic expenditure to determine responder status.

Baseline severity matters. Post-hoc analyses across the flibanserin trial program (BEGONIA, DAISY, VIOLET) suggest that women with more severe baseline distress experience larger absolute treatment effects (Simon et al., 2014). The cost-per-benefit ratio improves for these patients, though the trials were not powered for subgroup-specific economic conclusions.

Opportunity cost. Money and time spent on flibanserin are money and time not spent on alternatives: sex therapy, couples counseling, testosterone (off-label), bremelanotide, or addressing contributing medications. The opportunity cost calculation depends entirely on what else the patient has tried and what remains available.

Limitations of the Economic Evidence

The economic data around flibanserin has several gaps that warrant direct acknowledgment:

1. No prospective cost-utility analysis was embedded in BEGONIA or any other key trial. All QALY estimates are modeled, not measured.
2. The FSFI-to-QALY mapping remains unvalidated for HSDD-specific populations. Models borrow utility weights from general sexual function literature, introducing unknown bias.
3. Long-term adherence data are sparse. Real-world persistence with flibanserin appears low (one claims-based study found median duration of ~60 days), which changes both the cost and benefit sides of the equation (Kingsberg et al., 2017).
4. Generic entry has made branded economic models largely obsolete, but no published cost-effectiveness analysis uses generic pricing as the base case.
5. The REMS-associated friction costs (provider certification time, limited pharmacy networks) have not been formally incorporated into any published model.

The Bottom Line on Value

At branded prices, flibanserin does not meet conventional cost-effectiveness thresholds for most patients. At generic prices, it can meet those thresholds for patients with severe baseline distress who prove to be responders within 8 weeks. The most rational economic approach for an individual patient is a time-limited generic trial with a predefined stopping rule, exactly what the FDA label already recommends.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807-1815. PubMed
• Addyi (flibanserin) prescribing information. U.S. Food and Drug Administration. FDA Label
• Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
• Joffe HV, Chang C, Engstrom K, et al. FDA approval of flibanserin: treating hypoactive sexual desire disorder. N Engl J Med. 2016;374(2):101-104. PubMed
• Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633-640. PubMed
• Kingsberg SA, Krychman ML, Graham S, et al. Real-world prescription patterns of flibanserin. J Sex Med. 2017;14(12):1535-1542. PubMed
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797. PubMed
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404. PubMed